in TGRL composition, which can vary with an individual's diet and metabolism, affects the uptake by HAEC and correlates with endothelial inflammation and atherosclerosis.
Dysregulated expression of CAMs by EC and corresponding monocyte infiltration into the arterial wall are 2 early events in atherogenesis. In response to metabolic and inflammatory activation, vascular cell adhesion molecule-1 (VCAM-1) is upregulated on endothelium and bound by α4β1 integrins on activated monocytes as they arrest under arterial shear stress. 10 To understand the inflammatory mechanisms by which metabolic dysfunction of endothelium can lead to atherogenesis, we have developed an ex vivo model using cultured HAEC. 11 These studies revealed that TGRL isolated from human subjects after a moderately high-fat meal can prime either a proatherogenic or antiatherogenic state, defined as a net upregulation or downregulation of VCAM-1 expression relative to stimulation with tumor necrosis factor-α (TNFα). We reported that modulation of VCAM-1 expression and monocyte recruitment to HAEC under shear flow is dependent on both the quality of the TGRL, which correlates directly with the subject's body morphology and postprandial TG level, as well as the level of TNFα stimulation. 12 Specifically, we demonstrated that TGRL particles from subjects with sTG above a threshold of 225 mg/dL and a waist circumference >0.8 m were associated with enhanced VCAM-1 expression and the recruitment efficiency of monocytes, a harbinger of atherosclerosis. 12, 13 Our objective for this study was to elucidate the mechanisms underlying regulation of VCAM-1 expression. TGRL was isolated from individuals after a high-fat meal and its relative atherogenicity assessed by ex vivo analysis. We sought to elucidate the transcriptional mechanisms that could account for the selectivity in gene regulation of VCAM-1 versus ICAM-1 and E-selectin as a function of changes in postprandial particle content. The relative atherogenicity of TGRL mapped quantitatively to changes in particle TG density and nonesterified fatty acid (NEFA) content, whereas treatment with Ω3-PUFA reversed this effect. These findings reveal a mechanism for the specific regulation of VCAM-1 expression and monocyte adhesion in response to a high-fat meal through the reciprocal activity of interferon regulatory factor 1 (IRF-1) and the microRNA miR-126.
Methods
An expanded Methods section is available in the Online Data Supplement.
TGRL Isolation, Characterization, and Fatty Acid Analysis
Thirty-eight subjects were recruited according to institutional review board-approved protocols at the University of California, Davis. Venous blood was collected after a 12-hour overnight fast and again 3.5 hours after a standardized moderately high-fat meal (1230 calories, 42% from fat, 32% from saturated fat).
12,13 TGRL (ρ<1.0063 g/mL) were isolated by ultracentrifugation, 11 and the TG, ApoCIII, ApoE, cholesterol, and ApoB composition was analyzed by spectrophotometric assay (Polymedco Inc). All components were normalized to ApoB concentration and converted to density per particle (1 ApoB molecule per TGRL particle).
2 TGRL aliquots were spiked with a suite of lipid class surrogates and extracted for analysis of total fatty acid (TFA) and NEFA concentrations. Lipid residues were converted to fatty acid methyl esters and quantified by GC-MS (Agilent 6890GC-5973A MSD).
HAEC Culture and Treatment
HAEC (Genlantis) were cultured in Endothelial Growth Medium-2 (Lonza) and treated with TNFα (0.3 ng/mL, R&D) alone or simultaneously with TGRL (10 mg/dL ApoB) or FAs for 4 hours, unless otherwise indicated.
Flow Cytometry
HAEC were detached using enzyme-free cell dissociation buffer (Gibco), labeled with fluorescein-conjugated antibodies against human E-selectin, ICAM-1 or VCAM-1, and analyzed by FACScan flow cytometer (Becton Dickinson).
12

NF-κB and AP-1 Activation
NF-κB and AP-1 activation were measured by ELISA targeting active phospho-p65 and phospho-c-Jun in the nuclear extract.
Quantitative PCR
miR-126 and miR-17-3p expression were quantified using TaqMan MicroRNA Cells-to-CT (Applied Biosystems) and normalized to small nuclear RNA, RNU6B. VCAM-1 expression was quantified by TaqMan assay.
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VCAM-1 Reporter Assay
HAEC (5×10 5 ) were cotransfected with pGL3/hVCAM-1/-228-+12 14 and pGL4.75/hRluc/CMV at 10:1, using a 4 D-Nucleofector system (Lonza). After 18 hours, cells were treated as described and activity measured using a dual luciferase reporter system (Promega).
Chromatin Immunoprecipitation Assay
Cells were treated with TNFα (3 ng/mL) alone or simultaneously with TGRL or DHA for 2 hours, and chromatin was immunoprecipitated using ChIP-IT Express kit (Active Motif). IRF-1 binding VCAM-1 promoter was quantified by qPCR and normalized to input DNA.
Cell Transfection
Cells (5×10 human Irf-1 (OriGene), using a 4 D-Nucleofector system. After 48 hours (siRNA and miR-126 inhibitor) or 72 hours (plasmid), cells were treated as described followed by Western blot or flow cytometry analysis.
Monocyte Adhesion Assay
HAEC were grown in 24-well plates. Mononuclear cells (2×10 4 ) isolated from whole blood using Lymphoprep (Accurate Chemical & Scientific Corp) were added to each well and allowed to settle for 7 minutes at 37°C. After 3 washes with PBS, adhered monocytes were identified by CD14-positive fluorescence on a Nikon microscope.
Statistical Analysis
Data are presented as mean±SEM. Multiple groups were analyzed by ANOVA with Dunnett posttest or 2 groups compared using Student t test (GraphPad Prism). P<0.05 was considered significant. Correlations between groups were assessed using Pearson correlation coefficient (r). Multivariate and nonparametric statistics were performed using the Excel Add-In imDEV.
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Results
TGRL Modulates TNFα-Stimulated VCAM-1 Expression as a Function of Subject Lipoprotein Particle Composition
To investigate the effect of postprandial TGRL due to a high-fat meal on the inflammatory response of EC, we recruited 38 subjects exhibiting a broad range of body mass index (18- Tables I and II) . We examined the relative capacity of TGRL to modulate the inflammatory response of HAEC after 4 hours of low-dose TNFα stimulation that corresponds to 0.3 ng/mL, the EC 50 for CAM upregulation. 11 A correlation of VCAM-1, ICAM-1, and E-selectin expression as a function of TGRL particle density of TG, ApoCIII, ApoE, and cholesterol revealed the relative importance of these components in upregulation or downregulation relative to cytokine stimulation alone. TG and cholesterol were the most enriched components in TGRL particles isolated from postprandial serum (Online Table III) ; however, an individual's particle TG density yielded the most significant positive correlation in its capacity to alter VCAM-1 expression ( Figure 1A , Pearson r=0.6, P=0.002). We observed that subjects with postprandial TG above a threshold density routinely increased expression of VCAM-1, whereas a second subset decreased expression compared with TNFα stimulation alone. Moreover, particle densities of ApoCIII, ApoE, and cholesterol also exhibited threshold values in modulating VCAM-1 expression ( Figure 1B through 1D) . In contrast, most subjects elicited a net upregulation of ICAM-1 (18.7±2.4%) and E-selectin (16.9±11.8%) in response to TNFα and TGRL. This proinflammatory priming response of TGRL did not systematically correlate with particle composition (Online Figures I and II) . Since VCAM-1 is upregulated in nascent atherosclerotic plaques and changes in receptor expression correlate directly with the extent of monocyte recruitment to inflamed endothelium, 16 we refer to TGRL that enhanced TNFα-induced VCAM-1 membrane expression as proatherogenic and that which suppressed VCAM-1 expression as antiatherogenic. We determined that the TGRL elicited its atherogenic activity at the level of transcription using quantitative RT-PCR and a VCAM-1 luciferase reporter.
14 VCAM-1 promoter activity was increased by proatherogenic but decreased by antiatherogenic TGRL relative to that elicited by TNFα stimulation alone. This resulted in a significant difference in mRNA levels between the two groups (Online Figure III) . TGRL particles that elicited the strongest proatherogenic response were those with the highest concentrations of TG, ApoCIII, ApoE and cholesterol compared with particles characterized as antiatherogenic ( Figure 1E through 1H). The difference in TG between the 2 groups was significant at a threshold density of 530×10 −7 pg/particle, which corresponded to serum TG concentrations above 200 mg/dL (Online Figure IV) . Above this density, VCAM-1 expression was increased on average 16.2%, whereas below it was reduced by 18%. Proatherogenic TGRL contained ≈2.6-fold higher TG content compared with antiatherogenic (865±98×10 −7 pg/particle versus 329±34×10 −7 pg/particle). In contrast, TGRL uniformly enhanced TNFα-induced ICAM-1 and E-selectin expression independent of TG and lipoprotein density (Online Figures I and II). TGs contain a variety of glycerol-esterified fatty acids that can exert opposing effects on endothelial inflammation as a function of their level of saturation. 17 We examined proatherogenic and antiatherogenic TGRL from 13 subjects for total and nonesterified fatty acid constituents (Online Table  IV and Online Figure V ). The percentage of NEFA (1% to 2%) and relative abundance of each FA were consistent with observations from previous studies. 8 A principle component analysis revealed discrete groupings of the proatherogenic and antiatherogenic phenotypes. TGRL that had neutral effects on VCAM-1 expression segregated in a group between the proatherogenic and antiatherogenic phenotypes (Online Figure  V) . The relative abundance of NEFA provided the greatest discrimination between the samples. Online Table IV reveals that the TFA content was nearly equivalent between proatherogenic and antiatherogenic TGRL. However, NEFA SFAs, MUFAs, PUFAs, and HUFAs showed 3-, 2-, 1-, and 0.7-fold enrichment in antiatherogenic TGRL, respectively. Specifically, enriched in antiatherogenic TGRL were the SFAs palmitic (C16:0) and stearic acid (C18:0); the MUFAs palmitoleate (C16:1n7), oleic acid (C18:1n9), vaccenic acid (C18:1n7); and the PUFA linoleic acid (C18:2n6). Arachidonic acid (C20:4n6) was also significantly lower in the antiatherogenic TGRL. These results suggest that the specific fatty acid composition of the proatherogenic versus antiatherogenic TGRL accounts for the atherogenic bias of the cytokine-induced inflammatory response in HAEC.
PUFA Supplementation Suppresses the Atherogenic Response to TGRL
Because Ω3-PUFAs have exhibited beneficial effects in lowering sTG and were present at moderate levels in the subject's TGRL, we examined αLA and DHA for their association with inflammatory VCAM-1 expression. Treatment with DHA significantly inhibited VCAM-1 upregulation but not ICAM-1 in a dose-dependent manner, yielding ≈30% inhibition at 15 μmol/L DHA ( Figure 2A ). This inhibition was also observed for αLA, which induced a significant antiatherogenic effect in response to TNFα stimulation at 20 μmol/L ( Figure 2B ). In contrast, treatment with palmitic acid, the most abundant SFA in TGRL (Online Table IV) , at ≈10 μmol/L, did not alter TNFα-induced VCAM-1 or ICAM-1 upregulation (data not shown).
We next assessed whether PUFA along with TGRL would alter its relative proatherogenic or antiatherogenic effect in response to cytokine stimulation. Treatment with DHA (10 μmol/L) abrogated the proatherogenic influence of TGRL by decreasing VCAM-1 expression to the level stimulated with TNFα alone ( Figure 2C ). Likewise, superposition of DHA with antiatherogenic TGRL was additive in reducing VCAM-1 expression to below that of TNFα stimulation. As with TGRL treatment, DHA did not significantly reduce the net upregulation of ICAM-1 in response to TNF stimulation ( Figure 2D ). Collectively, these data demonstrate that exogenously applied PUFA at levels found in human serum exert an antiatherogenic effect that mimics that observed with the lower-density TG particles and that dietary FAs are a primary regulator of VCAM-1 production during inflammation.
TNFα-Induced NF-κB and AP-1 Activity Are Not Modulated by TGRL or PUFA
Because VCAM-1, ICAM-1, and E-selectin production depends on a conserved set of transcription factors that include NF-κB and AP-1, 14, 18 we measured their activation to gauge the priming activity of TGRL on TNFα stimulation. Neither TGRL nor DHA altered NF-κB activity in unstimulated cells. TNFα increased NF-κB activity, which was not significantly altered by the addition of proatherogenic or antiatherogenic TGRL or DHA ( Figure 3A) . Likewise, neither TGRL nor DHA altered the baseline or TNFα-induced activation of c-Jun ( Figure 3B ). These data reveal that TGRL did not augment activation of transcription factors that are common to VCAM-1 and ICAM-1, and motivated further analysis of distinct transcriptional mechanisms to explain the propensity for TGRL to differentially modulate VCAM-1.
TGRL and PUFA Modulate VCAM-1 Transcription Via an IRF-1-Dependent Mechanism
To account for the differential response in HAEC exerted by TGRL from our subject pool, we examined whether VCAM-1 expression was transcriptionally regulated at a motif that is distinct from ICAM-1. 14 We focused on IRF-1 because it has previously been reported that IRF-1 activity specifically modulates TNFα-induced VCAM-1 production.
14,19,20 IRF-1 protein expression tightly correlated with the extent of proatherogenic or antiatherogenic modulation of TNFα-induced VCAM-1 expression (Pearson r=0.6, P<0.001) ( Figure 4A ). This effect was attributed to the composition of TGRL as suggested by the positive correlation observed between particle TG density and cytokine-induced IRF-1 expression over a range from a 66% drop to a 43% increase from TNFα alone ( Figure 4B , Pearson r=0.65, P=0.01). As was the case with VCAM-1 expression, IRF-1 levels also increased with particle density of ApoCIII, ApoE and cholesterol (Online Figure VI) . Although TGRL did not itself induce CAM expression, a priming effect of TGRL on IRF-1 was observed in the absence of TNF . Proatherogenic TGRL enhanced basal expression of IRF-1 by 24%, whereas antiatherogenic TGRL suppressed expression by 11% ( Figure 4C ). After TNFα stimulation, proatherogenic TGRL enhanced IRF-1 expression by 26%, whereas antiatherogenic decreased it by 28% ( Figure 4C ). Likewise, DHA significantly suppressed TNFα-induced IRF-1 expression to a level similar to that observed with antiatherogenic TGRL (ie, −25%). Though basal expression of VCAM-1 in unstimulated HAEC is undetectable, the effects of DHA and TGRL on modulating IRF-1 expression were quantifiable leading to the conclusion that they edit VCAM-1 expression primarily during transcription activated by TNFα stimulation.
We next measured the binding of IRF-1 to the VCAM-1 promoter, using a chromatin immunoprecipitation (ChIP) assay to compare the activity of proatherogenic versus antiatherogenic TGRL on VCAM-1 during transcription. IRF-1 binding was enriched ≈50% relative to TNFα stimulation alone for proatherogenic TGRL ( Figure 4D ). In contrast, IRF-1 binding decreased by ≈30% for antiatherogenic TGRL and 74% in response to treatment with DHA, consistent with its capacity to diminish levels of IRF-1 and downregulate VCAM-1 expression. We confirmed that IRF-1 expression was suppressed to undetectable levels in the presence of siRNA targeting IRF-1 but not a scrambled control ( Figure 5A ). This resulted in a reduction of VCAM-1 by 33% and 23% when cells were treated with TNFα at 0.3 and 3 ng/mL, respectively. In contrast, ICAM-1 expression was not significantly altered by modulating IRF-1 levels ( Figure 5B and 5C). Treatment with siRNA to IRF-1 brought VCAM-1 expression down by 25% from that due to TNFα stimulation with proatherogenic TGRL (Figure 5D ). This level of inhibition was equivalent to that elicited by treatment with antiatherogenic TGRL. Remarkably, blocking IRF-1 activity with IRF-1 siRNA nullified the difference between proatherogenic TGRL versus antiatherogenic TGRL in regulating TNFα-stimulated VCAM-1 expression.
To evaluate the extent to which overexpression of IRF-1 increased inflammatory VCAM-1 expression, HAEC were transfected with a cDNA plasmid that elevated its expression in response to TNFα stimulation by 50% at 0.3 ng/mL and 61% at 3 ng/mL, without affecting ICAM-1 expression ( Figure 5E through 5G). The resulting amplification of VCAM-1 expression was comparable to that elicited by proatherogenic TGRL ( Figure  5H ). Thus, overexpression of IRF-1 reversed the antiatherogenic effect of TGRL on VCAM-1. Together, these data demonstrate the relative potency and specificity of IRF-1 in modulation of VCAM-1 transcription in response to TNFα and TGRL.
Posttranscriptional Modulation of VCAM-1 Expression Via miR-126
We hypothesized that the relative level and activity of miR-126 could in part account for the specificity of TGRL in modulating VCAM-1 production, since it is reported to suppress its expression posttranscriptionally without affecting TNFα-induced transcription or transcript stability. 21 Measurement of miR-126 induced by treatment with individual TGRLs revealed an inverse correlation with its capacity to modulate TNFα-induced VCAM-1 expression (Pearson r=−0.7, P<0.004) ( Figure 6A ). Expression of miR-126 was not altered by stimulation with TNFα alone, or treatment with TGRL alone, over culture duration up to 4 hours (data not shown). However, in response to cytokine superposed with proatherogenic TGRL the expression of miR-126 was decreased by 27% relative to TNFα, whereas antiatherogenic TGRL and DHA increased miR-126 expression by 20% and 30%, respectively ( Figure 6B ). Furthermore, DHA treatment elicited a dose-dependent increase in miR-126 and a corresponding inhibition in VCAM-1 expression in response to TNFα stimulation ( Figure 6C) . We examined the response in cells transfected with an antisense inhibitor to miR126, which elicited a 17% increase in VCAM-1 from control (Online Figure VIII) . The specificity of miR-126 in modulating VCAM-1 was examined by measuring expression of miR-17-3p, a specific modulator of ICAM-1 translation. 22 Treatment with either proatherogenic or antiatherogenic TGRL each decreased the expression of miR-17-3p by 20%, which correlated inversely with the observed 20% net increase in ICAM-1 in response to cytokine stimulation. Cotreatment with DHA and TNFα had no effect on Linear regression to data for n=25. B, Correlation between TGRL modulation of TNFα-induced IRF-1 expression and particle TG density; n=13. C, HAEC were treated for 4 hours with 10 μmol/L DHA or proatherogenic or antiatherogenic TGRL in the absence or presence of TNFα. IRF-1 protein expression was detected using Western blot and expressed relative to nonstimulated HAEC (*P<0.05; ***P<0.001 from nonstimulated; #P<0.05; ###P<0.001; n=5-14). D, HAEC were treated as described above except TNFα was applied at 3 ng/mL. Chromatin was immunoprecipitated at 2 hours. IRF-1 binding to VCAM-1 promoter was quantified by qPCR and normalized to input DNA (mean±SEM from 2 independent experiments). September 28, 2012 miR-17-3p expression( Figure 6D ). Taken together, these data reveal a posttranscriptional mechanism for editing cytokine-induced VCAM-1 expression in which miR-126 acts in a reciprocal manner to IRF-1 by increasing its expression in response to antiatherogenic TGRL or PUFA treatment of HAEC (Online Figure VII) .
Monocyte Adhesion to Activated HAEC Correlates With TGRL-Modulated VCAM-1 Expression
Monocyte arrest on HAEC is an early event in atherogenesis and dependent on the relative expression of endothelial VCAM-1. 12 We quantified VCAM-1-dependent adhesion under a variety of conditions in which its expression was altered at the transcriptional and posttranscriptional level (Figure 7) . Proatherogenic TGRL increased monocyte adhesion by ≈20%, whereas antiatherogenic TGRL and DHA decreased it by 20% to 30%. Similarly, silencing IRF-1 with siRNA decreased adhesion by ≈30%. Conversely, both IRF-1 overexpression and miR-126 inhibition had a similar effect of increasing monocyte adhesion by ≈30%. A striking finding was that VCAM-1 expression and monocyte recruitment were highly correlated regardless of the method of regulating VCAM-1 expression.
A 1% change in VCAM-1 expression corresponded to 1.5% change in monocyte adhesion that prescribed a constant slope over a dose range of TNFα from 0.03 to 3 ng/mL (Figure 7) . Together, these data demonstrate the functional importance of VCAM-1 regulation on monocyte adhesion in which expression was modulated physiologically by a subject's TGRL or engineered at the transcriptional and posttranscriptional level via IRF-1 and miR126.
Discussion
We applied ex vivo analysis of an individual's TGRL after consumption of a high-fat meal to examine the molecular mechanisms that skew arterial endothelium toward atherogenicity, characterized by increased VCAM-1 expression and monocyte adhesion. A direct correlation was measured between the density of TG, cholesterol, ApoCIII, and ApoE that constituted a subject's TGRL and its atherogenic potential to alter the inflammatory response to TNFα. A remarkable finding was that TGRL from a subset of subjects exerted an antiatherogenic effect by decreasing inflammatory expression of VCAM-1. In contrast, ICAM-1 and E-selectin expression were consistently upregulated with cytokine stimulation and TGRL, independent of its lipid or apolipoprotein content. These data reveal a distinct mechanism whereby the fatty acid composition of TGRL alters the kinetics of TNFα-induced VCAM-1 expression through fine-tuning the transcriptional and posttranscriptional regulators that also determine the efficiency of monocyte recruitment.
Previously, we reported that treatment of HAEC with TGRL isolated from the serum of fasting subjects did not alter the inflammatory response. 12 An intriguing question that arises is why individuals who consume an identical high-fat meal produce TGRL that elicit distinct ex vivo endothelial responses. 12 Circulating TGRL consist of chylomicrons and remnant particles synthesized by the gut and VLDL produced by processing in the liver. Its make-up varies as a function of an individual's level of carbohydrate intake, adipose tissue metabolism, and insulin sensitivity. 23 Moreover, heterogeneity in TGRL may reflect genetic variation in apolipoproteins and lipoprotein lipase that influence the rate and extent of particle clearance from the circulation. 2 Our studies focused on native TGRL particles that were not subjected to lipolysis or oxidation after isolation. We previously reported that LDLR-mediated endocytosis by HAEC accounted for ≈80% of native TGRL uptake that increased with stimulation by TNFα, but the extent of endocytosis did not vary significantly between donors. 12 Moreover, TGRL was not inherently inflammatory to endothelium but rather modulated the inflammatory response in a manner that correlated with a subject's triglyceride level and waist circumference. 11, 12 Based on these findings, we reasoned that differences in TGRL particle composition accounted for the variation in inflammatory modulation.
We observed that a subject's serum TG correlated closely with its density in freshly isolated TGRL particles, which above a threshold value of ≈200 mg/dL elicited an atherogenic response. Triglycerides are rich in esterified fatty acids that can elicit differential inflammatory responses as a function of their relative abundance on release by the action of lipoprotein lipase or other phospholipases in EC. 8 For example, the balance between neutral and oxidized FA could affect production of reactive oxygen species and inflammation in EC, 8 or these lipolysis products can serve as peroxisome proliferator-activated receptor (PPAR) agonists that downregulate TNFα-induced VCAM-1 expression. 24 However, it does not appear that the total FA content of TGRL was responsible for the relative atherogenecity of a subject's TGRL since it was equivalent between proatherogenic and antiatherogenic TGRL. In contrast, both saturated and unsaturated NEFA were enriched in antiatherogenic TGRL, whereas proatherogenic particles showed ≈65% enrichment in arachidonic acid (C20:4n6). Although NEFA only comprised 1% to 2% of the total fatty acid content detected in native TGRL, it is more likely to be directly available for uptake by EC in absence of lipoprotein lipase. Moreover, differences in NEFA content can result in activation of a variety of cellular responses through the action of PPARs 25 and Toll-like receptors (TLRs). 26 PPARs serve as regulators of metabolism and lipid-mediated inflammatory signaling, since they bind FAs as ligands with different affinities and specificities. PPARα is the most promiscuous, binding both SFA and PUFA, 25 and its agonist was reported to inhibit TNFα-induced VCAM-1 expression in human arterial EC. 27 Similarly, FAs differentially affect TLR4 activation as a function of their relative saturation. 26 Inflammatory effects of SFAs are mediated via TLR-4 and its deficiency can prevent insulin resistance and endothelial dysfunction. 28 We conclude that a distinct distribution of FA composition is in part responsible for the ex vivo atherogenic effect of an individual's TGRL on HAEC because we could statistically segregate the cohort of subjects into 3 discrete groups represented by proatherogenic, antiatherogenic, and neutral atherogenicity (Online Figure V) .
Several differences in the NEFA content between proatherogenic and antiatherogenic TGRL are worth highlighting. As a marker for de novo lipogenesis, palmitoleate (C16:1n7), which registered higher levels in antiatherogenic NEFA, is involved in conversion of glucose to fatty acids and elevated levels in plasma were associated with metabolic syndrome-resistant mice. 29 Oleic acid (C18:1n9), also elevated in antiatherogenic TGRL, can reduce the inflammatory effects of long-chain SFAs in HAECs through reducing cellular stearic acid incorporation and NF-κB activation. 30 Another study indicated that stearic acid (C18:0), oleic acid (C18:1n9), or vaccenic acid (C18:1n7) reduced H 2 O 2 -induced pulmonary artery endothelial cell injury. In contrast, linolenic acid (C18:3n6) and eicosatrienoic acid (20:3n3), both trending lower in antiatherogenic TGRL, enhanced H 2 O 2 -induced injury to pulmonary artery endothelial cell. 31 Our observations that higher levels of palmitoleate, oleic acid, vaccenic acid, and linoleic acid were associated with the beneficial effect of antiatherogenic TGRL on endothelial inflammatory response were consistent with these findings. Similarly, we found that antiatherogenic TGRL contained lower level of arachidonic acid (C20:4n6), a well-known inflammatory intermediate. Although SFA were previously shown to enhance the inflammatory response to cytokine in ECs and monocytes, 26 the inflammatory effect of SFA is somewhat controversial. Consistent with other studies, we found that exogenously added palmitic acid, the most abundant SFA in TGRL lipolysis products, 8 did not alter VCAM-1 or ICAM-1 upregulation relative to TNFα stimulation. 32 The findings that antiatherogenic TGRL contained more palmitic and stearic acids than did proatherogenic TGRL suggest a lesser role of SFA in skewing the inflammatory response in HAEC.
Studies on cultured EC have shown that Ω3-PUFA suppress the effects of cytokines 33 and proinflammatory mediators. 17 In line with these results, we found that treatment of HAEC with dietary levels of the PUFAs DHA and αLA suppressed cytokine-induced VCAM-1 (but not ICAM-1) expression in a dose-dependent manner. Moreover, PUFA supplementation nullified the upregulation of VCAM-1 induced by proatherogenic TGRL, consistent with a reported role for Ω3-PUFA in the selective regulation of CAM expression. 33 Although there was a trend for high αLA (P=0.07) in antiatherogenic TGRL, similar levels of DHA and other Ω3-PUFA were observed in proatherogenic TGRL, suggesting that the beneficial effect of PUFA may be not simply attributed to the absolute level of Ω3-PUFA. Instead, the antiatherogenic property may derive from a balance among different fatty acid species. For example, we found that proatherogenic TGRL displayed a higher ratio of AA(C20:4n6)+DTA (C22:4n6):EPA(C20:5n3)+DPA (C22:5n3)+DHA(C22:6n3), which is associated with metabolic syndrome. 34 In addition to fatty acids, we also observed an association between VCAM-1 expression and the postprandial concentration of cholesterol and apoCIII. This finding may partially account for the inflammatory effect of TGRL, given the potential association between high levels of serum cholesterol and apoCIII and inflammatory activation of EC. 8, 9 We sought to elucidate the transcriptional mechanisms underlying the selectivity in gene regulation of VCAM-1 versus ICAM-1 as a function of donor TGRL content. In response to cytokine stimulation, these adhesion receptors reach peak expression within 6 hours and are dependent on a conserved group of transcription factors that includes NF-κB and AP-1 14, 18 (Online Figure IX) . There have been conflicting reports as to the capacity of DHA to inhibit TNFα-induced NF-κB activation. 35, 36 We found that neither TGRL nor DHA modulated the cytokine-induced activation of NF-κB and AP-1 in HAEC treated with TNFα for 30 minutes, corresponding to maximum NF-κB assembly on the promoter region of VCAM-1. 18, 37, 38 Optimal VCAM-1 expression requires both constitutively bound SP-1, along with de novo production of IRF-1 by TNFα that acts cooperatively with NF-κB to induce a maximal response. 37, 38 Previous studies have reported that IRF-1-dependent regulation can either enhance or inhibit TNFα-induced VCAM-1 expression. 14, 19, 20, 37 Consistent with these studies, we observed that unstimulated HAEC expressed detectable levels of IRF-1, which increased steadily for up to 4 hours after TNFα stimulation. 37 Our data are the first to demonstrate that TGRL alone can modulate levels in basal expression of IRF-1 and in this manner amplify or suppress cytokine-induced regulation of VCAM-1 transcription and expression. Analysis of IRF-1 activity was confirmed by ChIP assay that clearly implicated TGRL-induced changes in relative expression of IRF-1 that edited up or down mRNA levels relative to TNFα stimulation alone. Confirmation that IRF-1 was a specific regulator of VCAM-1 transcription was provided by the use of siRNA and cDNA constructs. By specifically inhibiting IRF-1 expression, we abrogated proatherogenic TGRL amplification of VCAM-1 expression. Conversely, overexpression of IRF-1 effectively increased VCAM-1 in the presence of TNFα and nullified the effect of antiatherogenic TGRL. DHA supplementation mimicked the action of antiatherogenic TGRL in a dose-dependent manner by diminishing IRF-1 expression and assembly on the VCAM-1 promoter. A previous report has shown that DHA inhibited IRF-1 expression in macrophages, 39 but our data are the first to demonstrate DHA inhibition of IRF-1 expression in cultured EC. miR-126 is constitutively expressed in quiescent EC and binds to a complementary target site of the UTR of VCAM-1 mRNA, resulting in inhibition of mRNA translation and suppression of de novo protein synthesis. 21 Consistent with previous reports, TNFα alone did not alter the basal expression of miR-126, 21 nor did TGRL treatment alone. However, TNFα and TGRL combined to modulate miR-126 levels in a manner dependent on TGRL atherogenicity. The mechanisms underlying regulation of miR-126 are not well understood, although recent studies have demonstrated important roles for transcription factors of the Ets family and KLF2. 40 miR-126 expression in HAEC cotreated with TGRL and TNFα was inversely correlated with modulation in VCAM-1 expression. Moreover, DHA as well as antiatherogenic TGRL significantly increased miR-126 in a dose-dependent fashion, whereas SFAs had no effect. The extent of upregulation or downregulation of miR-126 expression was equivalent and reciprocal to that observed for IRF-1, producing a tight inverse correlation with subject's TGRL (Online Figure VII) . These data are the first to confirm that the antiatherogenic effect of PUFAs occurs in part at the posttranscriptional level via the action of miR-126.
A critical demonstration of the functional significance of dietary modulation of VCAM-1 expression is the effect of TGRL on monocyte arrest. The efficiency of adhesion varied in direct proportion to changes in VCAM-1 protein expression induced by TGRL, IRF-1, and miR-126, over a range of expression elicited by TNFα dose. Together, these data directly link modulation of IRF-1 and miR-126 in adhesion receptor specific regulation of VCAM-1 and monocyte adhesion to HAEC. Moreover, these data shed light on a mechanism by which PUFAs that lower circulating TG levels can modulate inflammation and possibly diminish an individual's risk of arterial plaque formation.
In summary, we reveal a putative mechanism by which TGRL modulates VCAM-1 production in HAEC through independent regulation of miR-126 and IRF-1 expression as a function of its FA and apolipoprotein constituents. In this manner, TGRL regulates both transcriptional and posttranscriptional pathways that superpose to edit VCAM-1 expression both in health and disease.
